ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Recommendation of "Moderate Buy" from Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has received an average rating of "Moderate Buy" from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $4.14.

A number of equities research analysts have weighed in on ALXO shares. HC Wainwright reiterated a "buy" rating and issued a $5.00 target price on shares of ALX Oncology in a report on Friday. Piper Sandler lifted their price objective on shares of ALX Oncology from $8.00 to $9.00 and gave the company an "overweight" rating in a research note on Thursday, March 6th. Jefferies Financial Group raised shares of ALX Oncology from a "hold" rating to a "buy" rating and increased their target price for the stock from $2.00 to $3.00 in a research note on Thursday, March 6th. Stifel Nicolaus reduced their price target on shares of ALX Oncology from $3.00 to $1.50 and set a "hold" rating for the company in a report on Friday. Finally, UBS Group dropped their price objective on shares of ALX Oncology from $4.00 to $2.20 and set a "buy" rating on the stock in a report on Monday, January 27th.

ALX Oncology Trading Up 8.9 %

Shares of ALXO stock traded up $0.08 on Friday, hitting $0.97. The company had a trading volume of 870,106 shares, compared to its average volume of 979,178. The stock's 50-day moving average is $1.37 and its two-hundred day moving average is $1.59. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The firm has a market cap of $51.34 million, a P/E ratio of -0.33 and a beta of 1.01. ALX Oncology has a twelve month low of $0.89 and a twelve month high of $17.83.

Remove Ads

Hedge Funds Weigh In On ALX Oncology

A number of hedge funds have recently added to or reduced their stakes in the stock. JSF Financial LLC bought a new position in shares of ALX Oncology in the fourth quarter valued at approximately $29,000. GSA Capital Partners LLP purchased a new stake in ALX Oncology in the 3rd quarter valued at $88,000. Barclays PLC lifted its stake in ALX Oncology by 243.6% during the 3rd quarter. Barclays PLC now owns 59,502 shares of the company's stock valued at $107,000 after acquiring an additional 42,185 shares in the last quarter. Sei Investments Co. purchased a new position in ALX Oncology during the 4th quarter worth $102,000. Finally, Bridgeway Capital Management LLC bought a new stake in shares of ALX Oncology in the 4th quarter worth $125,000. Institutional investors and hedge funds own 97.97% of the company's stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.